Keros Therapeutics, Inc. Lease, Cost
Keros Therapeutics, Inc. (KROS) reported Lease, Cost of $6.56 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-03-04
- Keros Therapeutics, Inc. lease, cost for the quarter ending 2024-12-31 was $1.58M, a 36.11% increase year-over-year.
- Keros Therapeutics, Inc. lease, cost for the quarter ending 2023-12-31 was $1.16M.
- Keros Therapeutics, Inc. lease, cost for the quarter ending 2023-09-30 was $1.60M.
- Keros Therapeutics, Inc. lease, cost for the quarter ending 2023-06-30 was $700.00K, a 250.00% increase year-over-year.
- Keros Therapeutics, Inc. lease, cost for fiscal 2025 was $6.56M, a 29.24% increase from fiscal 2024.
- Keros Therapeutics, Inc. lease, cost for fiscal 2024 was $5.08M, a 18.94% increase from fiscal 2023.
- Keros Therapeutics, Inc. lease, cost for fiscal 2023 was $4.27M, a 159.55% increase from fiscal 2022.
- Keros Therapeutics, Inc. lease, cost for fiscal 2022 was $1.64M, a 86.39% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month | Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $6.56M 10-K · filed 2026-03-04 | ||||
| 2024-12-31 | $1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $5.08M 10-K · filed 2026-03-04 | |||
| 2024-09-30 | $3.49M 10-Q · filed 2024-11-06 | ||||
| 2023-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $2.77M derived: sum of 2 quarters · filed 2025-02-26 | $3.47M derived: sum of 3 quarters · filed 2025-02-26 | $4.27M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $2.30M derived: sum of 2 quarters · filed 2024-11-06 | $3.10M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $1.50M 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | $800.00K 10-Q · filed 2023-05-04 | ||||
| 2022-12-31 | $1.64M 10-K · filed 2025-02-26 | $1.10M 10-K · filed 2023-03-03 | |||
| 2022-06-30 | $200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $400.00K 10-Q · filed 2023-08-07 | $922.00K derived: sum of 3 quarters · filed 2024-02-28 | $1.04M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-03-31 | $200.00K 10-Q · filed 2023-05-04 | $722.00K derived: sum of 2 quarters · filed 2024-02-28 | $842.00K derived: sum of 3 quarters · filed 2024-02-28 | ||
| 2021-12-31 | $522.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $642.00K derived: sum of 2 quarters · filed 2024-02-28 | $882.00K 10-K · filed 2024-02-28 | $587.00K 10-K · filed 2022-03-09 | |
| 2021-09-30 | $120.00K 10-Q · filed 2021-11-04 | $360.00K 10-Q · filed 2021-11-04 | |||
| 2020-12-31 | $119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $235.00K derived: sum of 2 quarters · filed 2022-03-09 | $468.00K 10-K · filed 2022-03-09 | ||
| 2020-09-30 | $116.00K 10-Q · filed 2021-11-04 | $349.00K 10-Q · filed 2021-11-04 | |||
| 2019-12-31 | $278.00K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |